Novel long non-coding RNA RP11-119F7.4 as a potential biomarker for the development and progression of gastric cancer

Abstract

Abstract. Long non-coding RNAs (lncRNAs) have been reported to be involved in gene dysregulation in numerous different types of cancer, and have subsequently emerged as a major series of regulatory molecules that participate in a broad range of biological and pathological processes. However, the correlation between the expression levels of lncRNAs and their clinical significance in gastric cancer remains unclear. The aim of the present study was to investigate the potential correlation between lncRNA RP11-119F7.4 expression and clinicopathological characteristics in gastric cancer, and to identify whether it can serve as a potential diagnostic biomarker of the disease. Total RNA was extracted from the tissues of 96 patients with gastric cancer, in addition to matched non-tumor adjacent tissues (NATs). Following reverse transcription, lncRNA RP11-119F7.4 expression levels were determined by quantitative polymerase chain reaction and the association with patient clinicopathological characteristics was further analyzed. A receiver operating characteristic (ROC) curve was constructed to determine the diagnostic value of RP11-119F7.4. The results demonstrated that RP11-119F7.4 expression was significantly downregulated in the gastric cancer tissues compared with the matched NATs (P<0.001) and was significantly associated with the macroscopic type (P=0.041) and Lauren grade (P=0.020). The area under the ROC curve was 0.637 (P<0.001). However, no statistically significant differences were observed between RP11-119F7.4 expression and patient survival. The results of the present study indicate that lncRNA RP11-119F7.4 may be involved in carcinogenesis and may prove useful as a biomarker for diagnosis and prognostic significance in patients with gastric cancer.

Integrated Analysis and MicroRNA Expression Profiling Identified Seven miRNAs Associated With Progression of Oral Squamous Cell Carcinoma

“…MicroRNAs (miRNAs) are a class of short noncoding RNA molecules, which regulate and degrade approximate one‐third of the protein‐coding mRNAs and directly or indirectly influence almost all cellular pathways (Sun et al, ). Recently, the number of miRNA expression profiling studies has increased rapidly.…”

Gastric cancer pathogenesis

“…The biogenesis and functions of lncRNAs and their roles in cancer have been recently reviewed . Aberrantly expressed lncRNAs have also been detected in GC and proposed as putative novel GC biomarkers …”

“…[22][23][24][25][26][27][28][29] Aberrantly expressed lncRNAs have also been detected in GC and proposed as putative novel GC biomarkers. [30][31][32][33][34][35] In an attempt to identify oncogenic lncRNAs in GC, Huang et al 36 used RNA sequencing to characterize nine GC and matched normal tissues, as well as GC and noncancer cell lines. They focused on the highly upregulated lncRNA RP3-416H24.1 (KRT7-AS), which is an antisense RNA transcribed from the negative strand of the keratin 7, type II protein-coding gene (KRT7).…”

NONHSAT076754 aids ultrasonography in predicting lymph node metastasis and promotes migration and invasion of papillary thyroid cancer cells

“…Some recent reports have demonstrated that lncRNAs play a critical role in cancer development and progression and that they have the potential to serve as diagnostic and prognostic biomarkers in gastric cancer [15], prostate cancer [16], and hepatocellular carcinoma [17], among other cancers. LncRNAs are tumor-specific and are also very stable in serum, urine and other easily obtainable body fluids [18], which indicates that they are good candidate tumor biomarkers.…”